Abstract
Legionella pneumophila is the predominant cause of Legionnaires disease, a severe and potentially fatal form of pneumonia. Recently, we identified an ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) from L. pneumophila, termed Lpg1905, which enhances intracellular replication of L. pneumophila in eukaryotic cells. Lpg1905 is the first prokaryotic member of the CD39/NTPDase1 family of enzymes, which are characterized by the presence of five apyrase conserved regions and the ability to hydrolyze nucleoside tri- and diphosphates. Here we examined the substrate specificity of Lpg1905 and showed that apart from ATP and ADP, the enzyme catalyzed the hydrolysis of GTP and GDP but had limited activity against CTP, CDP, UTP, and UDP. Based on amino acid residues conserved in the apyrase conserved regions of eukaryotic NTPDases, we generated five site-directed mutants, Lpg1905E159A, R122A, N168A, Q193A, and W384A. Although the mutations E159A, R122A, Q193A, and W384A abrogated activity completely, N168A resulted in decreased activity caused by reduced affinity for nucleotides. When introduced into the lpg1905 mutant strain of L. pneumophila, only N168A partially restored the ability of L. pneumophila to replicate in THP-1 macrophages. Following intratracheal inoculation of A/J mice, none of the Lpg1905 mutants was able to restore virulence to an lpg1905 mutant during lung infection, thereby demonstrating the importance of NTPDase activity to L. pneumophila infection. Overall, the kinetic studies undertaken here demonstrated important differences to mammalian NTPDases and different sensitivities to NTPDase inhibitors that may reflect underlying structural variations.
Legionella pneumophilia is the major causative agent of Legionnaires disease, a severe systemic disease characterized by acute pneumonia. During infection of the human lung, L. pneumophila is internalized by alveolar macrophages where the bacteria replicate within an intracellular vacuole that evades fusion with the endocytic pathway. Instead the L. pneumophila containing vacuole intercepts early secretory vesicles and following maturation exhibits properties of the endoplasmic reticulum (1–3). Establishment of the unique Legionella vacuole and the ability to replicate within eukaryotic cells requires the Dot/Icm type IV secretion system, which translocates bacterial effector proteins into the cytoplasm of the host cell (4–7).
The ability of L. pneumophila to replicate within mammalian cells appears to be a consequence of its association in the natural environment with free living protozoa. The three sequenced L. pneumophila genomes encode an unusually high number of proteins with similarity to eukaryotic proteins (8–10), which may interfere with host cell processes by functional mimicry (11). We recently showed that Lpg1905 from L. pneumophila is a secreted member of the CD39/NTPDase1 family of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases; gene family ENTPD).5 NTPDases are extremely rare in bacteria, and Lpg1905 is the first prokaryotic member of the CD39/NTPDase1 family to be characterized (12).
NTPDases are important ectonucleotidases that are characterized by the presence of five apyrase conserved regions (abbreviated as ACR1 to ACR5) and by the ability to hydrolyze NTPs and nucleoside diphosphates (NDPs) to the monophosphate form. Mammalian NTPDases play a major role in the regulation of blood clotting, inflammatory processes, and immune responses (13–16). At least eight NTPDases exist in humans, and of these CD39/NTPDase1, CD39L1/NTPDase2, CD39L3/NTPDase3, and NTPDase8 are located on the cell surface. Other members of this family may be associated with intracellular organelles and membranes or may be secreted (17, 18).
A number of parasites also possess functional NTPDases, and these have been implicated in host-pathogen interactions and virulence. Toxoplasma gondii is an important pathogen of immunocompromised people, including pregnant women, that expresses two isoforms of NTPDase, one of which is particularly associated with virulent strains (19–22). Schistosoma mansoni, the cause of a chronic debilitating disease known as intestinal schistosomiasis (15, 23), also exhibits classic ecto-NTPDase activity. Other parasites that express virulence-associated NTPDase activity include Trypanosoma spp. Trichomonas vaginalis, Leishmania spp., and Entamoeba histolytica (24–29).
In mammalian systems, CD39 on both T regulatory cells (30) and endothelial cells (31) suppresses immune responses and thrombotic reactions, respectively. It is possible that microbiological expression of NTPDase-like ecto-enzymes may also decrease protective host responses. However, investigations into the role of parasite NTPDases in virulence have been hampered by the difficulty of genetic manipulation in these pathogens and/or the requirement of NTPDases for intrinsic purine scavenging and therefore parasitic viability. Despite the lack of mechanistic roles for these enzymes in infection, NTPDases have been proposed as possible targets for the development of novel anti-infective agents (32).
The relative ease of genetic manipulation in L. pneumophila led us to investigate the contribution of NTPDase activity to L. pneumophila infection in a mouse model of Legionnaires disease. In addition, we characterized the enzyme kinetics of Lpg1905 hydrolysis of ATP, ADP, GTP, and GDP to examine functional differences between microbial and mammalian NTPDases that may reflect structural differences.
EXPERIMENTAL PROCEDURES
Bacterial Strains, Plasmids, and Culture Conditions—Bacterial strains and plasmids used in this study are listed in Table 1. L. pneumophilia strains were cultured in N-(2-acetamido)-2-aminoethanesulfonic acid-buffered yeast extract broth or on buffered charcoal yeast extract plates (33). When required, kanamycin and chloramphenicol were added to the medium at 25 and 6 μg/ml, respectively.
TABLE 1.
Bacterial strain/plasmid | Relevant characteristics | Source |
---|---|---|
L. pneumophila | ||
130b | O1; clinical isolate | Ref. 81 |
130b (pMIP) | 130b carrying pMIP | Ref. 12 |
lpg1905::km | lpg1905 insertion mutant of 130b (KmR) | Ref. 12 |
lpg1905::km (pMIP) | lpg1905::km carrying pMIP | Ref. 12 |
lpg1905::km (pMIP:lpg1905) | lpg1905::km carrying pMIP:lpg1905 | Ref. 12 |
lpg1905::km (pMIP:lpg1905E159A) | lpg1905::km carrying pMIP:lpg1905E159A | Ref. 12 |
lpg1905::km (pMIP:lpg1905R122A) | lpg1905::km carrying pMIP:lpg1905R122A | This study |
lpg1905::km (pMIP:lpg1905N168A) | lpg1905::km carrying pMIP:lpg1905N168A | This study |
lpg1905::km (pMIP:lpg1905Q193A) | lpg1905::km carrying pMIP:lpg1905Q193A | This study |
lpg1905::km (pMIP:lpg1905W384A) | lpg1905::km carrying pMIP:lpg1905W384A | This study |
E. coli | ||
XL-1 Blue | recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac (F′ proAB+ lacIqlacZΔM15 Tn10) (TetR) | Stratagene |
BL21 (DE3) | F- ompT hsdSB(rB—mB-)gal dcm (DE3) | Novagen |
Plasmids | ||
pGEM-T Easy | 3015 bp, AmpR, high copy cloning | Promega |
pGEM:lpg1905 | Full-length lpg1905 cloned into BamHI/HindIII | This study |
pGEM:lpg1905R122A | Arg122 mutated to Ala in pGEM:lpg1905 | This study |
pGEM:lpg1905N168A | Asn168 mutated to Ala in pGEM:lpg1905 | This study |
pGEM:lpg1905Q193A | Gln193 mutated to Ala in pGEM:lpg1905 | This study |
pGEM:lpg1905W384A | Trp384 mutated to Ala in pGEM:lpg1905 | This study |
pRSETb | 2897bp, AmpR, E. coli expression vector with a bacteriophage T7 promoter and N-terminal polyhistidine (His6) tag | Invitrogen |
pRSET:lpg1905 | Truncated enzymatically active form of lpg1905 cloned into EcoRI/HindIII (missing the first 34 amino acids corresponding to a putative signal peptide sequence) | Ref. 12 |
pRSET:lpg1905E159A | Glu159 mutated to Ala in pRSET:lpg1905 | Ref. 12 |
pRSET:lpg1905R122A | Arg122 mutated to Ala in pRSET:lpg1905 | This study |
pRSET:lpg1905N168A | Asn168 mutated to Ala in pRSET:lpg1905 | This study |
pRSET:lpg1905Q193A | Gln193 mutated to Ala in pRSET:lpg1905 | This study |
pRSET:lpg1905W384A | Trp384 mutated to Ala in pRSET:lpg1905 | This study |
pMIP | 9523 bp, pMMB207 with the promoter region of mip cloned into SacI/XbaI (CmR) | Ref. 37 |
pMIP:lpg1905 | pMIP with full-length lpg1905 cloned into BamHI and HindIII | Ref. 12 |
pMIP:lpg1905E159A | pMIP with full-length lpg1905E159A cloned into BamHI and HindIII | Ref. 12 |
pMIP:lpg1905R122A | pMIP with full-length lpg1905R122A cloned into BamHI and HindIII | This study |
pMIP:lpg1905N168A | pMIP with full-length lpg1905N168A cloned into BamHI and HindIII | This study |
pMIP:lpg1905Q193A | pMIP with full-length lpg1905Q193A cloned into BamHI and HindIII | This study |
pMIP:lpg1905W384A | pMIP with full-length lpg1905W384A cloned into BamHI and HindIII | This study |
Purification of Recombinant His6-tagged Lpg1905—As described previously (12), recombinant His6-tagged Lpg1905 (rLpg1905) was expressed using pRSET:lpg1905 in Escherichia coli BL21 (DE3) C41 strain and purified using nickel column chromatography. Protein was also purified from E. coli BL21 carrying the empty pRSET vector to provide a control for contaminating NTPases and NDPases in some experiments (mock purification). For detailed analysis of the enzyme kinetics of rLpg1905, further purification was performed. Pooled fractions were dialyzed overnight against 1 liter of 20 mm Tris, pH 7.9, 50 mm NaCl at 4 °C. Dialyzed sample was concentrated using Amicon 10,000-Da molecular mass cut-off concentrators (Millipore) to a volume of 1 ml and filtered using a centrifugal filter (Ultrafree-MC; Millipore). The sample was loaded onto an S200 S16/60 column (GE Healthcare) using the buffer 20 mm Tris, pH 7.9, 150 mm NaCl at a flow rate of 1 ml/min. 2-ml fractions were collected and analyzed using Coomassie-stained SDS-PAGE. The fractions containing rLpg1905 were pooled and concentrated using Amicon 10,000-Da molecular mass cut-off concentrators before aliquots were stored at –80 °C. Protein concentration was measured using the Bio-Rad protein assay.
Assays for Enzymatic Activity of rLpg1905 and Mutant Derivatives—To determine the divalent cation preference of rLpg1905, incubation buffer containing 30 mm Tris-HCl, pH 7.4, 2 mm ATP, or 2 mm ADP and between 0 mm and 5 mm Mg2+, Ca2+, or Zn2+ ions was used. rLpg1905 was added to the reaction at 0.2 ng/μl, and the reaction was incubated at 37 °C for 10 min. Where indicated 0.1 mm EDTA or EGTA was added to the reaction. The reaction was stopped by the addition of malachite green dye reagent (1.5% w/v ammonium molybdate, 0.122% w/v malachite green hydrochloride, 6 n sulfuric acid, 0.18% v/v Tween). Incubation buffer containing 30 mm Tris-HCl and 2 mm Mg2+ and a variety of substrate concentrations as indicated in the figure legends (31) was used to determine the pH preference of rLpg1905 and to analyze the kinetics of rLpg1905 and rLpg1905N168A as well as in the assessment of enzyme inhibition by POM-1 (Na6[H2W12O40]) and POM-6 ((NH4)18[NaSb9W21O86]) (34). To examine enzyme kinetics a linear production of phosphate is required, and the enzyme concentration was adjusted to achieve this. To assess ATPase activity 0.01 ng/μl of protein was used, and to assess ADPase activity 0.02 ng/μl of protein was used. The reactions were incubated at 37 °C for 10 min and stopped by the addition of 5% trichloroacetic acid. To analyze hydrolysis of non-adenine nucleotides, recombinant proteins were diluted into 100 μl of assay buffer (8 mm CaCl2, 5 mm levamisole, 50 mm Trisbase, 50 mm imidazole, 150 mm NaCl, pH 7.5) at a concentration of 0.2 ng/μl (for ATPase and ADPase activity), 0.4 ng/μl (for GTPase and GDPase activity), and 2 ng/μl (for CTPase, CDPase, UTPase, and UDPase activity). 25 μl of 300 μm of substrate (ATP, ADP, GTP, GDP, CTP, CDP, UTP, or UDP) was added to the wells, and the plates were incubated at 37 °C for 5–60 min. 25 μl of malachite green dye reagent was added to each well to stop the reaction (12). For all experiments Pi release was measured with reference to an appropriate range of inorganic phosphate standards (35, 36). To compare the hydrolysis of different substrates, the results were normalized (where required) by conversion to μmol Pi/min/mg enzyme before determining the relative levels of activity.
Site-directed Mutagenesis of Lpg1905—Site-directed mutagenesis was performed using the QuikChange® II site-directed mutagenesis kit (Stratagene) on pRSET:lpg1905 to mutate Arg122 to Ala (R122A), Asn168 to Ala (N168A), and Gln193 to Ala, (Q193A), giving rise to pRSET:lpg1905R122A, pRSET:lpg1905N168A, and pRSET:lpg1905Q193A. Primer pairs used are listed in Table 2. To mutate Trp384 to Ala (W384A) primers 5′-CGGGATCCGACAACAAAATATACACAATGTACCAATCG-3′ and 5′-CCCAAGCTTTCAAGCGCGGTGAAGCACGACTCCAATTGTCGCATCGAGATTTTGTTC-3′ were used to amplify full-length lpg1905 containing the W384A mutation (underlined, base changes in bold) and cloned into pGEM using the pGEM-T-Easy Kit (Promega) according to the manufacturer's specifications. This plasmid was then used as template to amplify lpg1905 lacking the first 34 amino acids and cloned into pRSET as described previously (12) to generate pRSET:lpg1905W384A. All of the mutations were confirmed by nucleotide sequencing.
TABLE 2.
Sequences | Use |
---|---|
5′-CGCAACAGCTGGTATGGCACTACTACCCCAATCAC-3′ | Sense and anti-sense oligonucleotides to mutate Lpg1905 Arg122 to Ala |
5′-GTGATTGGGGTAGTAGTGCCATACCAGCTGTTGCG-3′ | |
5′-GACTGGCTTGCTGTAGCTTATAAACTTGATAC-3′ | Sense and anti-sense oligonucleotides to mutate Lpg1905 Asn168 to Ala |
5′-GTATCAAGTTTATAAGCTACAGCAAGCCAGTC-3′ | |
5′-GGGCGGCGCTTCCGTTGCAATTGTCTTTCCAATG-3′ | Sense and anti-sense oligonucleotides to mutate Lpg1905 Gln193 to Ala |
5′-CATTGGAAAGACAATTGCAACGGAAGCGCCGCCC-3′ |
Purification of Site-directed Mutant Derivatives of Lpg1905—rLpg1905E159A was expressed and purified as described previously (12). rLpg1905R122A, rLpg1905N168A, rLpg1905Q193A, and rLpg1905W384A were all expressed in derivatives of E. coli BL21 (DE3) and purified using nickel column chromatography, as described for rLpg1905E159A (12). Assays to assess hydrolysis of nucleoside tri- and diphosphates were performed as described for rLpg1905.
Complementation of lpg1905::km Mutant with Plasmids Expressing Site-directed Mutant Derivatives of Lpg1905—Genes for the expression of site-directed Lpg1905 mutant proteins in L. pneumophila lpg1905::km were reconstructed to include the native ribosome-binding site and signal peptide and cloned into the Legionella expression vector pMIP (37). Because the large size of pMIP precluded use of the QuikChange® II site-directed mutagenesis kit (Stratagene), primers 5′-CGGGATCCGACAACAAAATATACACAATGTACCATTCG-3′ and 5′-CCCAAGCTTTCAAGCGCGGTGAAGCACGACTC-3′ were used to amplify full-length lpg1905 including the ribosome-binding site for cloning into pGEM-T-Easy (Promega). To mutate Arg122 to Ala, Asn168 to Ala, and Gln193 to Ala, the QuikChange® II site-directed mutagenesis kit was then used as described for mutagenesis of pRSET:lpg1905 to generate pGEM:lpg1905R122A, pGEM:lpg1905N168A, and pGEM:lpg1905Q193A. Following BamHI/HindIII digestion, each mutant derivative was then cloned into pMIP, generating pMIP:lpg1905R122A, pMIP:lpg1905N168A, pMIP: lpg1905Q193A, and pMIP:lpg1905W384A, which were then electroporated into L. pneumophila 130b lpg1905::km as described previously (38). All of the mutations and insertions were confirmed by nucleotide sequencing. To confirm secretion of the mutant proteins by L. pneumophila, supernatants of overnight broth cultures were precipitated with trichloroacetic acid, and immunoblotting was performed using monospecific anti-Lpg1905 antibodies, as described previously (12).
Intracellular Replication of L. pneumophila in THP-1 Macrophages—The ability of L. pneumophila 130b and recombinant derivatives to replicate over a 72-h time period in the monocytic cell line THP-1 was assayed as described previously (37). Briefly, THP-1 cells were seeded into 24-well tissue culture trays (Sarstedt, Leicestershire, UK) at a density of 5×105 cells/well and pretreated with 10–8 m phorbol 12-myristate 13-acetate for 36–48 h to induce differentiation into adherent macrophage-like cells. Stationary phase L. pneumophila strains were resuspended in tissue culture medium and added to THP-1 cells at a multiplicity of infection of 5. After incubation for 2 h, the cells were treated with 100 μg/ml gentamicin for 1 h to kill extracellular bacteria. Infected macrophages were then washed three times with phosphate-buffered saline before incubation with tissue culture maintenance medium. At 3, 24, 48, and 72 h THP-1 cells were lysed with 0.05% digitonin. Viable numbers of L. pneumophila were enumerated by serial dilution and plating onto buffered charcoal yeast extract agar.
Competitive Pulmonary Infections of A/J Mice—Intratracheal inoculations of A/J mice with L. pneumophila were performed as described previously except that bacteria were introduced by intubation rather than incision (39, 40). All of the animal infections were approved by the Monash University Animal Ethics Committee, application number SOBSB/B/2006/21. 6–8-week-old female A/J mice (Jackson Laboratory) were anesthetized with ketamine (75 mg/kg) and xylazine (15 mg/kg), and the mice were intubated with a 20-gauge intravenous catheter over guide wire, facilitated by transillumination of the larynx using a fiber optic light. Approximately 105 colony-forming units of each L. pneumophila strain under investigation were then instilled in 25 μl of phosphate-buffered saline followed by 25 μl of air through the catheter using a 100-μl microsyringe attached to a blunt 20 gauge needle. Mutant derivatives of L. pneumophila were introduced into the lung in a 1:1 ratio with the wild type strain or the wild type strain carrying pMIP as indicated. At 72 h following infection mice were euthanized, and their lung tissue was isolated. The tissue was homogenized in 5 ml of phosphate-buffered saline, and complete host cell lysis was achieved by incubation in 0.1% saponin (Sigma) for 10 min at 37 °C. Serial dilutions of the homogenate were plated onto both plain and antibiotic selective buffered charcoal yeast extract agar to determine the number of viable bacteria and the ratio of wild type to mutant bacteria colonizing the lung. The competitive index (CI) was calculated as the proportion of mutant to wild type bacteria recovered from mice divided by the proportion of mutant to wild type bacteria in the inoculum (41).
RESULTS
Hydrolysis of ATP and ADP by Lpg1905 Is Dependent on Divalent Metal Cations—All of the mammalian surface-located NTPDases are inactive in the absence of Mg2+ or Ca2+ cations (13). The majority of parasitic enzymes are stimulated by Mg2+ or Ca2+ (28, 42–44), but Zn2+ has also been shown to stimulate ecto-NTPDase activity of Trypanosoma brucei (27). In contrast, ecto-NTPDase activity of Leishmania spp. is only stimulated by Mg2+ and not Ca2+ (24, 45). To characterize the co-factor requirements of Lpg1905 further, we determined the divalent cation preference of the enzyme and tested whether a range of cations could be utilized. We demonstrated that rLpg1905 required divalent metal cations for activity, which was stimulated by Zn2+, Mg2+, or Ca2+ (Fig. 1). Maximal ATPase and ADPase activity was obtained with 1–2 mm Mg2+, although Zn2+ was able to stimulate ADPase activity to the same extent as Mg2+. The presence of chelating agents 0.1 mm EGTA (which has low affinity for Mg2+) and 0.1 mm EDTA (which has low affinity for Ca2+) were also used with buffers containing either Mg2+ or Ca2+, as appropriate, to demonstrate that the observed activity was not due to contamination of the assay buffer by other cations.
Lpg1905 Is Highly Active Only at a Near Neutral pH—The effect of pH on both ATPase and ADPase activity of Lpg1905 was evaluated over a pH range of 5–9. Optimal activity was observed at pH 7.4 for both substrates (Fig. 2, A and B). Significant hydrolysis of both ATP and ADP was still observed at pH 8, but negligible hydrolysis of either substrate occurred at pH 9 or at pH 6 or lower. This suggests that the physiological site of activity is a pH-neutral environment such as the early Legionella replicative vacuole, the macrophage cytosol, or the extracellular environment.
Lpg1905 Efficiently Hydrolyzes Both ATP and ADP but Displays a Slight Preference for ATP—Substrate preference for nucleoside triphosphates and diphosphates varies among members of the ecto-NTPDase family of enzymes. For example, CD39/NTPDase1 hydrolyzes both ATP and ADP with similar efficiency, whereas NTPDase2 preferentially exhibits ATPase activity (13). We performed detailed enzyme kinetics of Lpg1905 using ATP and ADP as substrates, at pH 7.4 in the presence of 2 mm Mg2+. At a concentration of 0.01 and 0.02 ng/μl of protein, respectively, hydrolysis of ATP and ADP was initially linear (Fig. 2, C and D), with linear regression giving an R2 value of 0.95 (ATP hydrolysis) and 0.88 (ADP hydrolysis) at 45 min. We then analyzed the effects of varying substrate concentration when production of phosphate was linear to determine kinetic parameters for both ATP and ADP hydrolysis. Plotting of the initial velocities as a function of substrate concentration for both ATP and ADP hydrolysis revealed normal Michaelis-Menten kinetics for both substrates (Fig. 3). GraphPad Prism5 software was used to perform nonlinear regression analysis, determining a Km value of 0.4 mm for ATP and 1.0 mm for ADP, suggesting a higher affinity of Lpg1905 for ATP, although the Vmax was similar for both substrates (1182 μmol Pi/min/mg for ATP hydrolysis and 996 μmol Pi/min/mg for ADP hydrolysis). The Kcat/Km ratio was then calculated to measure substrate specificity. For ATP hydrolysis a Kcat/Km ratio of 1.2 × 108/m/min was obtained, whereas for ADP hydrolysis a Kcat/Km ratio of 7.9 × 107/m/min was obtained, demonstrating the preference of Lpg1905 for ATP. However, the Kcat/Km ratios for both substrates are in the upper range of observed values for enzyme-substrate reactions (46), indicating that Lpg1905 is very efficient at hydrolyzing both ATP and ADP.
ATPase Activity of Lpg1905 Is Inhibited by POM-1 and POM-6 but with Differing Efficacies—Polyoxometalate compounds have recently been identified as potent inhibitors of ecto-NTPDases (34). POM-1 (Na6[H2W12O40]) inhibits NTPDase1 and NTPDase3 with similar efficacy, with Ki values of 2.58 and 3.26 μm, respectively (34). POM-1 is also able to inhibit NTPDase2, albeit less efficiently, with a Ki value of 28.8 μm (34). In contrast, POM-6 ((NH4)18[NaSb9W21O86]) inhibits NTPDase2 and NTPDase3, with Ki values of 3.94 and 3.77 μm but is a very weak inhibitor of NTPDase1, with an IC50 greater than 1 mm (34). Here we tested the ability of these particular polyoxometalates to inhibit rLpg1905 activity to determine whether a microbial ecto-NTPDase exhibited increased or decreased susceptibility to inhibition compared with mammalian NTPDases. To achieve 100% inhibition of rLpg1905 activity with POM-1, an ATP concentration of 0.025 mm was used in the presence of 0.001–1 mm POM-1. Enzyme velocity was plotted against log10 of the inhibitor concentration, and nonlinear curve fitting was performed using GraphPad Prism5 software to determine the Ki (Fig. 4A). This revealed that POM-1 is a relatively weak inhibitor of rLpg1905, exhibiting a Ki value of 267 μm, compared with the ability of this compound to inhibit the three mammalian NTPDases (34). To achieve 100% inhibition with POM-6, an ATP concentration of 0.1 mm was used, in the presence of 0.001–0.4 mm of POM-6 (Fig. 4B). In contrast to POM-1, POM-6 was more effective at inhibiting rLpg1905 with a Ki value of 67 μm, demonstrating that it also possessed greater inhibitory activity against rLpg1905 than against CD39/NTPDase1. POM-6 was more effective, however, at inhibiting rat NTPDase2 and NTPDase3 than rLpg1905. Although the differences between POM-1 and POM-6 inhibition compared with mammalian NTPDases were minor, these results nevertheless suggested functional differences between rLpg1905 and mammalian ecto-NTPDases.
Lpg1905 Efficiently Hydrolyzes Guanosine Nucleoside Tri- and Diphosphates but Has Low Activity against Uridine or Cytidine Nucleotides—Numerous NTPDases from parasites have been shown to hydrolyze non-adenine nucleotides as well as adenine nucleotides (21, 27, 42, 43, 47–50). Therefore, we tested the ability of rLpg1905 to hydrolyze GTP, GDP, UTP, UDP, CTP, and CDP. rLpg1905 efficiently hydrolyzed both GTP and GDP (Fig. 5), and whereas GTP hydrolysis occurred at a similar level to ATP, hydrolysis of GDP was approximately twice that observed for ADP (Fig. 5). In contrast, despite utilizing a higher concentration of enzyme in an attempt to demonstrate consistent activity against CTP, CDP, UTP, and UDP, only low levels of hydrolysis of these substrates were observed (Fig. 5). From these results, we concluded that the likely role of Lpg1905 in L. pneumophila virulence relates to the hydrolysis of adenine and/or guanine nucleotides.
Mutation of Conserved Residues Present in the ACRs Affects the Level of Catalytic Activity but Not Substrate Specificity—Extensive site-directed mutagenesis studies have been carried out on both CD39/NTPDase1 and NTPDase3, examining the importance of various conserved residues to catalytic activity (51–58). Previously we showed that, similar to CD39/NTPDase1 and NTPDase3, mutation to alanine of Glu159 in ACR3 (E159A) of rLpg1905 abolishes both ATP and ADP hydrolysis (12, 53, 56). As expected, rLpg1905E159A was also unable to catalyze the hydrolysis of GTP, GDP, UTP, UDP, CTP, or CDP (data not shown). To examine the contribution of other conserved amino acids to catalytic function, we generated four amino acid changes within ACR2–5 and examined the effect of the mutations on overall levels of catalytic activity and substrate specificity. In contrast to similar mutations in NTPDase3 (56), mutation of any one of Arg122 (ACR2), Gln226 (ACR4), and Trp384 (ACR5) to alanine abolished NTPDase activity against all substrates (data not shown). Only mutation of Asn168 (ACR3) to alanine resulted in residual enzyme activity. The activity of rLpg1905N168A toward all substrates, except CDP was decreased to ∼35–50% of wild type activity (ATP, 49 ± 6%; ADP, 52 ± 15%; GTP, 49 ± 16%; GDP, 40 ± 12%; CTP, 44 ± 11%; CDP, 76 ± 14%; UTP, 37 ± 5%; UDP, 33 ± 8%). Therefore this mutation had a different effect on Lpg1905 activity compared with NTPDase3, where mutation of the corresponding asparagine residue to alanine resulted in a decrease of NTPase activity but not NDPase activity for all substrates (56). Collectively these results reinforce the importance of conserved residues in ACR2–5 to NTPDase activity. Furthermore, it highlights important enzymatic differences between microbial enzymes and mammalian enzymes because the mutations introduced into Lpg1905 had different effects on enzyme activity compared with the same mutations in NTPDase3.
Because significant catalytic activity was retained only for rLpg1905N168A, we compared the kinetics of this enzyme to rLpg1905. A time course analysis revealed that rLpg1905N168A hydrolyzes 1 mm ATP and ADP at a much lower rate than rLpg1905 (Fig. 6, A and B). Plotting of the initial velocities as a function of substrate concentration for both ATP and ADP hydrolysis by rLpg1905N168A revealed normal Michaelis-Menten kinetics for both substrates but with a relatively increased Km for the mutant enzyme (Fig. 6, C and D). The Km was increased 1.3-fold for ATP hydrolysis and 3-fold for ADP hydrolysis, demonstrating a lower affinity of rLpg1905N168A for both ATP and ADP. This suggested decreased substrate affinity was the reason for the observed decrease in activity and may indicate that Asn168 is located in the substrate-binding site of Lpg1905.
The Catalytic Activity of Lpg1905 Is Important for Bacterial Replication in Tissue Culture Models of L. pneumophila Infection—Previously, we established that an lpg1905 mutant of L. pneumophila suffers an intracellular replication defect in THP-1 macrophages (12). Furthermore, we showed that the catalytic activity of Lpg1905 is important for bacterial replication, because complementation of the lpg1905 mutant with a plasmid, pMIP, expressing wild type Lpg1905, but not inactive Lpg1905E159A, restored intracellular replication to wild type levels (12). In this study, we confirmed the necessity of catalytic activity for replication of L. pneumophila in THP-1 macrophages. The lpg1905 mutant was complemented with pMIP expressing Lpg1905R122A, Q193A, N168A, or W384A, and we confirmed that the mutated forms of Lpg1905 were produced and secreted by L. pneumophila (Fig. 7A). Complemented strains were then tested for their ability to replicate in THP-1 macrophages. Complementation of the lpg1905 mutant with pMIP expressing Lpg1905R122A, Q193A, or W384A resulted in an intracellular replication defect similar to that seen for the lpg1905 mutant carrying pMIP alone or expressing Lpg1905E159A (Fig. 7B). In contrast, the introduction of pMIP expressing Lpg1905N168A into the lpg1905 mutant resulted in partial complementation (Fig. 7B). The intermediate level of replication of L. pneumophila expressing Lpg1905N168A suggested that the quantity of catalytic activity was important for intracellular replication of L. pneumophila.
Catalytic Activity of Lpg1905 Is Required for Virulence in the A/J Mouse Model of Legionnaires Disease—Intratracheal inoculation of A/J mice results in an acute pneumonia resembling L. pneumophila infection in immunocompetent humans (59). After 72 h, bacteria are gradually cleared from the lungs of A/J mice without overt signs of illness (59). This model has been used previously to test isogenic mutants of L. pneumophila for a role in virulence (40, 60). Here 6–8-week-old A/J mice were infected with a 1:1 ratio of wild type L. pneumophila and the lpg1905 mutant. Viable numbers of each strain were determined 72 h after infection by plating serial dilutions of lung homogenate onto CYE agar and CYE agar containing kanamycin. Growth on nonselective media represented total colony-forming units isolated from the lung, and kanamycin-resistant colonies represented colony-forming units of the lpg1905 mutant. The CI was calculated as the proportion of mutant to wild type bacteria recovered from mice divided by the proportion of mutant to wild type bacteria in the inoculum. A mutant with a CI of less than 0.5 is considered to be attenuated (61). The CI for the lpg1905 mutant was 0.18, demonstrating that this mutant is attenuated for virulence in vivo (Fig. 7C). Similar to in vitro tissue culture models (12), introduction of the pMIP complementation vector into L. pneumophila exacerbated the virulence defect of the lpg1905 mutant. The CI of the lpg1905 mutant carrying pMIP in competition with wild type L. pneumophila carrying pMIP was 0.014 (Fig. 7C). Complementation of the lpg1905 mutant with pMIP expressing Lpg1905 restored virulence to the mutant; however, complementation of the lpg1905 mutant with pMIP expressing any of Lpg1905E159A, R122A, Q193A, N168A, or W384A was not able to complement the virulence defect in vivo (Fig. 7C). Therefore the catalytic activity of Lpg1905 is important for its function during infection. The lack of even partial complementation observed for L. pneumophila expressing Lpg1905N168A suggested that the quantity of Lpg1905 activity may also be important for its virulence function. This could indicate that Lpg1905 plays an additional role in vivo that is not evident in simple tissue culture models.
DISCUSSION
Previously we showed that Lpg1905 is a novel prokaryotic ecto-NTPDase, similar to CD39/NTPDase1, which enhances the replication of L. pneumophila in eukaryotic cells (12). In this study, we defined the enzymatic properties of Lpg1905 and demonstrated that apart from ATP and ADP, Lpg1905 also cleaves GTP and GDP with similar efficiency to ATP and ADP, respectively. In contrast, the enzyme was not able to utilize CTP, CDP, UTP, or UDP to any great extent. These results suggest that it is the ATP/ADPase and/or GTP/GDPase activity of Lpg1905 that is most important for L. pneumophila virulence. Interestingly, amino acid changes that are known to affect the level of activity and substrate preference for NTPDase3 (56, 58) unexpectedly abolished activity of Lpg1905. Mutation of Asp168 to alanine was the only amino acid change that did not result in complete inactivation; however, this mutation had little effect on the NTPase:NDPase ratio or substrate specificity. Therefore we were not able to assess the relative contribution of ATP/ADPase and/or GTP/GDPase activity to virulence. Nevertheless, our mutational analysis of Lpg1905 demonstrated definitively that enzymatic activity is closely linked to L. pneumophila replication in macrophages and virulence in mice.
At this stage the major site of Lpg1905 activity during infection is unclear, although potentially the enzyme could exert an effect in both intracellular and extracellular environments. As an intracellular pathogen, L. pneumophila may utilize Lpg1905 to cleave ATP to AMP inside cells. A possible consequence of this could be a rise in the AMP:ATP ratio and activation of AMP-activated protein kinase (62). Activation of AMP-activated protein kinase has numerous effects on cell cycle and mitochondrial function, all of which could provide a more beneficial environment for intracellular survival and replication of L. pneumophila (63, 64). In addition, there is evidence suggesting that activation of AMP-activated protein kinase results in inhibition of the production of proinflammatory cytokines such as interleukin-1β (65). Another potential role for Lpg1905 in virulence is modulation of extracellular levels of ATP. The importance of extracellular ATP as a “danger signal” is becoming increasingly evident (66). ATP stimulates signaling through purinergic type 2 (P2) receptors, which results in the modulation of host immune and inflammatory responses and apoptosis (13, 67). ATP triggers the release of proinflammatory cytokines including interleukin-1β, interleukin-2, and interferon γ (68, 69). Mammalian ecto-NTPDases modulate this response by controlling the level of extracellular ATP. For example, CD39 expressed on regulatory T cells mediates immune suppression through the hydrolysis of ATP (30, 70) and on endothelium is a crucial thromboregulatory factor (71). Extracellular ATP also stimulates phagolysosome fusion and killing of intracellular Mycobacterium spp. by human macrophages in a P2 receptor-dependent manner (72, 73). In addition, another intracellular bacterial pathogen Porphyromonas gingivalis inhibits P2 receptor mediated apoptosis by secreting an extracellular nucleoside diphosphate kinase, an ATP-consuming enzyme (74). Together these studies suggest that the control of extracellular ATP and P2 receptor signaling may benefit an intracellular pathogen such as L. pneumophila by delaying P2 receptor-dependent phagolysosome fusion, stimulation of inflammation, and/or apoptosis.
We also demonstrated that Lpg1905 cleaves GTP and GDP. Although L. pneumophila does not require the addition of purines for growth, the supplementation of medium with guanine can increase growth rate in vitro (75). However, L. pneumophila does not appear to possess a 5′-nucleotidase (9, 10), which is required for the hydrolysis of GMP to guanine, suggesting that the hydrolysis of GTP and GDP may be related to a role in the manipulation of host cell pathways rather than purine salvage. The conversion of GTP to GDP inside cells is critical to intracellular signaling and vesicle trafficking pathways (76). Indeed, L. pneumophila recruits the host cell GTPase Rab1 to the replicative vacuole where the Dot/Icm effector SidM/DrrA prevents recycling of GDP from the Legionella phagosome (77–79). Interfering with levels of intracellular GTP and GDP may be another way in which Lpg1905 from L. pneumophila modulates host cell signaling.
A number of parasites express surface-located or secreted NTPDases that have been implicated in virulence, and the external location of these enzymes makes them desirable drug targets (32). Recently, a new class of drugs, N-alkylaminoalkanethiosulfuric acids, was shown to partially inhibit a surface-located NTPDase from S. mansoni, which may form the basis of the anti-schistosomal efficacy of these compounds (80). However, because membrane-associated and surface-located mammalian NTPDases, such as CD39, play important roles in thromboregulation and modulation of the immune response (13, 30, 70), it is important that antimicrobial compounds designed to inhibit the NTPDases of pathogens do not adversely affect the function of human NTPDases. Although in this study we found differing effects of the promising NTPDase inhibitors, POM-1 and POM-6, on Lpg1905 activity compared with mammalian NTPDases, these effects were relatively minor and not therapeutically useful given that any residual activity against mammalian NTPDases would be pharmacologically unacceptable. Nevertheless, these functional differences provide some evidence that the rational design of novel anti-microbial agents based on structural information could be possible. Indeed the differing effects of altering corresponding amino acids in Lpg1905 and NTPDase3 on enzyme activity support the existence of significant structural differences. The structural resolution of a number of microbial and mammalian NTPDases would greatly advance our understanding of the catalytic mechanism of NTPDase enzymes and form the basis for a rational approach to the development of inhibitors with different specificities and targets.
Acknowledgments
We are grateful to Associate Professor Robert N. Pike (Monash University) for use of protein purification equipment.
This work was supported, in whole or in part, by National Institutes of Health Grants HL57307, HL63972, and HL076540 (to S. C. R.). This work was also supported by an Australian National Health and Medical Research Council grant (to E. L. H., A. J. F. d'A., and P. J. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Footnotes
The abbreviations used are: NTPDase, nucleoside triphosphate diphosphohydrolase; ACR, apyrase conserved region; NDP, nucleoside diphosphate; CI, competitive index; P2, purinergic type 2.
References
- 1.Robinson, C. G., and Roy, C. R. (2006) Cell Microbiol. 8 793–805 [DOI] [PubMed] [Google Scholar]
- 2.Swanson, M. S., and Isberg, R. R. (1995) Infect. Immun. 63 3609–3620 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kagan, J. C., and Roy, C. R. (2002) Nat. Cell Biol. 4 945–954 [DOI] [PubMed] [Google Scholar]
- 4.Cambronne, E. D., and Roy, C. R. (2006) Traffic 7 929–939 [DOI] [PubMed] [Google Scholar]
- 5.Segal, G., and Shuman, H. A. (1998) Mol. Microbiol. 30 197–208 [DOI] [PubMed] [Google Scholar]
- 6.Nagai, H., Kagan, J. C., Zhu, X., Kahn, R. A., and Roy, C. R. (2002) Science 295 679–682 [DOI] [PubMed] [Google Scholar]
- 7.Berger, K. H., and Isberg, R. R. (1993) Mol. Microbiol. 7 7–19 [DOI] [PubMed] [Google Scholar]
- 8.Bruggemann, H., Cazalet, C., and Buchrieser, C. (2006) Curr. Opin. Microbiol. 9 86–94 [DOI] [PubMed] [Google Scholar]
- 9.Cazalet, C., Rusniok, C., Bruggemann, H., Zidane, N., Magnier, A., Ma, L., Tichit, M., Jarraud, S., Bouchier, C., Vandenesch, F., Kunst, F., Etienne, J., Glaser, P., and Buchrieser, C. (2004) Nat. Genet. 36 1165–1173 [DOI] [PubMed] [Google Scholar]
- 10.Chien, M., Morozova, I., Shi, S., Sheng, H., Chen, J., Gomez, S. M., Asamani, G., Hill, K., Nuara, J., Feder, M., Rineer, J., Greenberg, J. J., Steshenko, V., Park, S. H., Zhao, B., Teplitskaya, E., Edwards, J. R., Pampou, S., Georghiou, A., Chou, I. C., Iannuccilli, W., Ulz, M. E., Kim, D. H., Geringer-Sameth, A., Goldsberry, C., Morozov, P., Fischer, S. G., Segal, G., Qu, X., Rzhetsky, A., Zhang, P., Cayanis, E., De Jong, P. J., Ju, J., Kalachikov, S., Shuman, H. A., and Russo, J. J. (2004) Science 305 1966–1968 [DOI] [PubMed] [Google Scholar]
- 11.de Felipe, K. S., Pampou, S., Jovanovic, O. S., Pericone, C. D., Ye, S. F., Kalachikov, S., and Shuman, H. A. (2005) J. Bacteriol. 187 7716–7726 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Sansom, F. M., Newton, H. J., Crikis, S., Cianciotto, N. P., Cowan, P. J., d'Apice, A. J., and Hartland, E. L. (2007) Cell Microbiol. 9 1922–1935 [DOI] [PubMed] [Google Scholar]
- 13.Robson, S. C., Sevigny, J., and Zimmermann, H. (2006) Purinergic Signal. 2 409–430 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Vasconcelos, E. G., Nascimento, P. S., Meirelles, M. N., Verjovski-Almeida, S., and Ferreira, S. T. (1993) Mol. Biochem. Parasitol. 58 205–214 [DOI] [PubMed] [Google Scholar]
- 15.Vasconcelos, E. G., Ferreira, S. T., Carvalho, T. M., Souza, W., Kettlun, A. M., Mancilla, M., Valenzuela, M. A., and Verjovski-Almeida, S. (1996) J. Biol. Chem. 271 22139–22145 [DOI] [PubMed] [Google Scholar]
- 16.Handa, M., and Guidotti, G. (1996) Biochem. Biophys. Res. Commun. 218 916–923 [DOI] [PubMed] [Google Scholar]
- 17.Knowles, A. F., and Li, C. (2006) Biochemistry 45 7323–7333 [DOI] [PubMed] [Google Scholar]
- 18.Zimmermann, H. (2001) Drug Dev. Res. 52 44–56 [Google Scholar]
- 19.Asai, T., O'Sullivan, W. J., and Tatibana, M. (1983) J. Biol. Chem. 258 6816–6822 [PubMed] [Google Scholar]
- 20.Asai, T., and Kim, T. (1987) Zentralbl. Bakteriol. Mikrobiol. Hyg. [A] 264 464–467 [DOI] [PubMed] [Google Scholar]
- 21.Asai, T., Miura, S., Sibley, L. D., Okabayashi, H., and Takeuchi, T. (1995) J. Biol. Chem. 270 11391–11397 [DOI] [PubMed] [Google Scholar]
- 22.Bermudes, D., Peck, K. R., Afifi, M. A., Beckers, C. J., and Joiner, K. A. (1994) J. Biol. Chem. 269 29252–29260 [PubMed] [Google Scholar]
- 23.DeMarco, R., Kowaltowski, A. T., Mortara, R. A., and Verjovski-Almeida, S. (2003) Biochem. Biophys. Res. Commun. 307 831–838 [DOI] [PubMed] [Google Scholar]
- 24.Berredo-Pinho, M., Peres-Sampaio, C. E., Chrispim, P. P., Belmont-Firpo, R., Lemos, A. P., Martiny, A., Vannier-Santos, M. A., and Meyer-Fernandes, J. R. (2001) Arch. Biochem. Biophys. 391 16–24 [DOI] [PubMed] [Google Scholar]
- 25.Pinheiro, C. M., Martins-Duarte, E. S., Ferraro, R. B., Fonseca de Souza, A. L., Gomes, M. T., Lopes, A. H., Vannier-Santos, M. A., Santos, A. L., and Meyer-Fernandes, J. R. (2006) Exp. Parasitol. 114 16–25 [DOI] [PubMed] [Google Scholar]
- 26.Meyer-Fernandes, J. R., Saad-Nehme, J., Peres-Sampaio, C. E., Belmont-Firpo, R., Bisaggio, D. F., Do Couto, L. C., Fonseca De Souza, A. L., Lopes, A. H., and Souto-Padron, T. (2004) Parasitol. Res. 93 41–50 [DOI] [PubMed] [Google Scholar]
- 27.de Souza Leite, M., Thomaz, R., Fonseca, F. V., Panizzutti, R., Vercesi, A. E., and Meyer-Fernandes, J. R. (2007) Exp. Parasitol. 115 315–323 [DOI] [PubMed] [Google Scholar]
- 28.de Jesus, J. B., de Sa Pinheiro, A. A., Lopes, A. H., and Meyer-Fernandes, J. R. (2002) Z. Naturforsch. [C] 57 890–896 [DOI] [PubMed] [Google Scholar]
- 29.Tasca, T., Bonan, C. D., De Carli, G. A., Sarkis, J. J., and Alderete, J. F. (2005) Parasitology 131 71–78 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J. F., Enjyoji, K., Linden, J., Oukka, M., Kuchroo, V. K., Strom, T. B., and Robson, S. C. (2007) J. Exp. Med. 204 1257–1265 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Kaczmarek, E., Koziak, K., Sevigny, J., Siegel, J. B., Anrather, J., Beaudoin, A. R., Bach, F. H., and Robson, S. C. (1996) J. Biol. Chem. 271 33116–33122 [DOI] [PubMed] [Google Scholar]
- 32.Levano-Garcia, J., Mortara, R. A., Verjovski-Almeida, S., and DeMarco, R. (2007) Biochem. Biophys. Res. Commun. 352 384–389 [DOI] [PubMed] [Google Scholar]
- 33.Feeley, J. C., Gibson, R. J., Gorman, G. W., Langford, N. C., Rasheed, J. K., Mackel, D. C., and Baine, W. B. (1979) J. Clin. Microbiol. 10 437–441 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Muller, C. E., Iqbal, J., Baqi, Y., Zimmermann, H., Rollich, A., and Stephan, H. (2006) Bioorg. Med. Chem. Lett. 16 5943–5947 [DOI] [PubMed] [Google Scholar]
- 35.Geladopoulos, T. P., Sotiroudis, T. G., and Evangelopoulos, A. E. (1991) Anal. Biochem. 192 112–116 [DOI] [PubMed] [Google Scholar]
- 36.Robson, S. C., Kaczmarek, E., Siegel, J. B., Candinas, D., Koziak, K., Millan, M., Hancock, W. W., and Bach, F. H. (1997) J. Exp. Med. 185 153–163 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Newton, H. J., Sansom, F. M., Bennett-Wood, V., and Hartland, E. L. (2006) Infect. Immun. 74 1683–1691 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Chen, D. Q., Huang, S. S., and Lu, Y. J. (2006) Microbiol. Res. 161 246–251 [DOI] [PubMed] [Google Scholar]
- 39.Hardy, C. L., Kenins, L., Drew, A. C., Rolland, J. M., and O'Hehir, R. E. (2003) Am. J. Respir. Crit. Care Med. 167 1393–1399 [DOI] [PubMed] [Google Scholar]
- 40.Rossier, O., Starkenburg, S. R., and Cianciotto, N. P. (2004) Infect. Immun. 72 310–321 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Mundy, R., Pickard, D., Wilson, R. K., Simmons, C. P., Dougan, G., and Frankel, G. (2003) Mol. Microbiol. 48 795–809 [DOI] [PubMed] [Google Scholar]
- 42.de Aguiar Matos, J. A., Borges, F. P., Tasca, T., Bogo, M. R., De Carli, G. A., da Graca Fauth, M., Dias, R. D., and Bonan, C. D. (2001) Int. J. Parasitol. 31 770–775 [DOI] [PubMed] [Google Scholar]
- 43.Jesus, J. B., Lopes, A. H., and Meyer-Fernandes, J. R. (2002) Vet. Parasitol. 103 29–42 [DOI] [PubMed] [Google Scholar]
- 44.Torres, C. R., Vasconcelos, E. G., Ferreira, S. T., and Verjovski-Almeida, S. (1998) Eur. J. Biochem. 251 516–521 [DOI] [PubMed] [Google Scholar]
- 45.Meyer-Fernandes, J. R., Dutra, P. M., Rodrigues, C. O., Saad-Nehme, J., and Lopes, A. H. (1997) Arch. Biochem. Biophys. 341 40–46 [DOI] [PubMed] [Google Scholar]
- 46.Stroppolo, M. E., Falconi, M., Caccuri, A. M., and Desideri, A. (2001) Cell Mol. Life Sci. 58 1451–1460 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Faria-Pinto, P., Meirelles, M. N., Lenzi, H. L., Mota, E. M., Penido, M. L., Coelho, P. M., and Vasconcelos, E. G. (2004) Parasitology 129 51–57 [DOI] [PubMed] [Google Scholar]
- 48.Asai, T., Howe, D. K., Nakajima, K., Nozaki, T., Takeuchi, T., and Sibley, L. D. (1998) Exp. Parasitol. 90 277–285 [DOI] [PubMed] [Google Scholar]
- 49.Fietto, J. L., DeMarco, R., Nascimento, I. P., Castro, I. M., Carvalho, T. M., de Souza, W., Bahia, M. T., Alves, M. J., and Verjovski-Almeida, S. (2004) Biochem. Biophys. Res. Commun. 316 454–460 [DOI] [PubMed] [Google Scholar]
- 50.Fonseca, F. V., Fonseca de Souza, A. L., Mariano, A. C., Entringer, P. F., Gondim, K. C., and Meyer-Fernandes, J. R. (2006) Exp. Parasitol. 112 76–84 [DOI] [PubMed] [Google Scholar]
- 51.Schulte am Esch, J., 2nd, Sevigny, J., Kaczmarek, E., Siegel, J. B., Imai, M., Koziak, K., Beaudoin, A. R., and Robson, S. C. (1999) Biochemistry 38 2248–2258 [DOI] [PubMed] [Google Scholar]
- 52.Drosopoulos, J. H. (2002) Arch. Biochem. Biophys. 406 85–95 [DOI] [PubMed] [Google Scholar]
- 53.Drosopoulos, J. H., Broekman, M. J., Islam, N., Maliszewski, C. R., Gayle, R. B., III, and Marcus, A. J. (2000) Biochemistry 39 6936–6943 [DOI] [PubMed] [Google Scholar]
- 54.Grinthal, A., and Guidotti, G. (2000) Biochemistry 39 9–16 [DOI] [PubMed] [Google Scholar]
- 55.Smith, T. M., and Kirley, T. L. (1999) Biochemistry 38 321–328 [DOI] [PubMed] [Google Scholar]
- 56.Yang, F., Hicks-Berger, C. A., Smith, T. M., and Kirley, T. L. (2001) Biochemistry 40 3943–3950 [DOI] [PubMed] [Google Scholar]
- 57.Kirley, T. L., Yang, F., and Ivanenkov, V. V. (2001) Arch. Biochem. Biophys. 395 94–102 [DOI] [PubMed] [Google Scholar]
- 58.Smith, T. M., Lewis Carl, S. A., and Kirley, T. L. (1999) Biochemistry 38 5849–5857 [DOI] [PubMed] [Google Scholar]
- 59.Brieland, J., Freeman, P., Kunkel, R., Chrisp, C., Hurley, M., Fantone, J., and Engleberg, C. (1994) Am. J. Pathol. 145 1537–1546 [PMC free article] [PubMed] [Google Scholar]
- 60.Newton, H. J., Sansom, F. M., Dao, J., McAlister, A. D., Sloan, J., Cianciotto, N. P., and Hartland, E. L. (2007) Infect. Immun. 75 5575–5585 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Kelly, M., Hart, E., Mundy, R., Marches, O., Wiles, S., Badea, L., Luck, S., Tauschek, M., Frankel, G., Robins-Browne, R. M., and Hartland, E. L. (2006) Infect. Immun. 74 2328–2337 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Kemp, B. E., Mitchelhill, K. I., Stapleton, D., Michell, B. J., Chen, Z. P., and Witters, L. A. (1999) Trends Biochem. Sci. 24 22–25 [DOI] [PubMed] [Google Scholar]
- 63.Menze, M. A., Clavenna, M. J., and Hand, S. C. (2005) Am. J. Physiol. 288 R501–R510 [DOI] [PubMed] [Google Scholar]
- 64.Bokko, P. B., Francione, L., Bandala-Sanchez, E., Ahmed, A. U., Annesley, S. J., Huang, X., Khurana, T., Kimmel, A. R., and Fisher, P. R. (2007) Mol. Biol. Cell 18 1874–1886 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Giri, S., Nath, N., Smith, B., Viollet, B., Singh, A. K., and Singh, I. (2004) J. Neurosci. 24 479–487 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Burnstock, G. (2007) Cell. Mol. Life Sci. 64 1471–1483 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Bours, M. J., Swennen, E. L., Di Virgilio, F., Cronstein, B. N., and Dagnelie, P. C. (2006) Pharmacol. Ther. 112 358–404 [DOI] [PubMed] [Google Scholar]
- 68.Ferrari, D., Chiozzi, P., Falzoni, S., Dal Susino, M., Melchiorri, L., Baricordi, O. R., and Di Virgilio, F. (1997) J. Immunol. 159 1451–1458 [PubMed] [Google Scholar]
- 69.Langston, H. P., Ke, Y., Gewirtz, A. T., Dombrowski, K. E., and Kapp, J. A. (2003) J. Immunol. 170 2962–2970 [DOI] [PubMed] [Google Scholar]
- 70.Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Hopner, S., Centonze, D., Bernardi, G., Dell'Acqua, M. L., Rossini, P. M., Battistini, L., Rotzschke, O., and Falk, K. (2007) Blood 110 1225–1232 [DOI] [PubMed] [Google Scholar]
- 71.Enjyoji, K., Sevigny, J., Lin, Y., Frenette, P. S., Christie, P. D., Esch, J. S., 2nd, Imai, M., Edelberg, J. M., Rayburn, H., Lech, M., Beeler, D. L., Csizmadia, E., Wagner, D. D., Robson, S. C., and Rosenberg, R. D. (1999) Nat. Med. 5 1010–1017 [DOI] [PubMed] [Google Scholar]
- 72.Fairbairn, I. P., Stober, C. B., Kumararatne, D. S., and Lammas, D. A. (2001) J. Immunol. 167 3300–3307 [DOI] [PubMed] [Google Scholar]
- 73.Kusner, D. J., and Barton, J. A. (2001) J. Immunol. 167 3308–3315 [DOI] [PubMed] [Google Scholar]
- 74.Yilmaz, O., Yao, L., Maeda, K., Rose, T. M., Lewis, E. L., Duman, M., Lamont, R. J., and Ojcius, D. M. (2008) Cell Microbiol. 10 863–875 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Pine, L., Franzus, M. J., and Malcolm, G. B. (1986) J. Clin. Microbiol. 23 163–169 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Scheffzek, K., and Ahmadian, M. R. (2005) Cell. Mol. Life Sci. 62 3014–3038 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Ingmundson, A., Delprato, A., Lambright, D. G., and Roy, C. R. (2007) Nature 450 365–369 [DOI] [PubMed] [Google Scholar]
- 78.Murata, T., Delprato, A., Ingmundson, A., Toomre, D. K., Lambright, D. G., and Roy, C. R. (2006) Nat. Cell Biol. 8 971–977 [DOI] [PubMed] [Google Scholar]
- 79.Machner, M. P., and Isberg, R. R. (2007) Science 318 974–977 [DOI] [PubMed] [Google Scholar]
- 80.Luiz Oliveira Penido, M., Resende, D. M., Vianello, M. A., Humberto da Silveira Bordin, F., Jacinto, A. A., Dias, W. D., Montesano, M. A., Nelson, D. L., Marcos Zech Coelho, P., and Vasconcelos, E. G. (2007) Eur. J. Pharmacol. 570 10–17 [DOI] [PubMed] [Google Scholar]
- 81.Engleberg, N. C., Drutz, D. J., and Eisenstein, B. I. (1984) Infect. Immun. 44 222–227 [DOI] [PMC free article] [PubMed] [Google Scholar]